Week’s Option Activity (12/27 ~ 1/9)

The following stocks had notable activity in their options during the past week(s): $GERN (12/27): 663 JUN 5.0 strike Calls (stock at $5.10) were purchased for 1.40 or total cost of $92,820. Buyer makes money if stock trades above $6.40 by June expiration. $CHTP (12/31): 5,500 JAN 4.0 strike Puts (stock at $4.40) were purchased […]

November 15-EOD

It has been a relatively quiet day in biotech land, which is fine as it has been a busy week. I saw more of the same with a mixed performance and stocks reacting to news specific to the company and those with little news were drifting. 1. I have been spending a lot of time […]

November 11- EOD

I am gone for a little while and the market goes crazy, bounces, and then we have today which has both sell offs and rallies. To be honest, it is difficult to get a good read on the sector sentiment writ large at this point and at those times it seems the best bet is […]

November 4- EOD

(This was from yesterday. Due to the server issues, I am not sure many of you saw it, so I am reposting.) I take one day to not write an EOD and biotechs sell off. Well, they have been weak for awhile so no real surprise but at least the selling does not seemed related […]

October 31- EOD

ARIA is doing its best to single handedly crush biotech sentiment and grind it into a bloody pulp. As I have said before, if this is the bursting of a real speculative bubble then we have another five to ten years of selling (I think it took tulip prices over a century to recover and […]

October 30- EOD

The sector seems almost perilously balanced between putting in a solid base for the next leg higher and setting up for another leg lower. The freefall that we have seen in recent weeks has slowed but volumes remain pathetic (especially in the small cap space), which means buyers are not quite interested. Of course, when […]

October 15- EOD

While this may surprise you (not) but it was another macro driven day (I know you are probably getting as tired of reading that as I am of writing it). Volume also seems to be drying up as investor simply sit on their hands and wait for Washington to get off of their hands. Despite […]

October 14- EOD

It was another macro day and will be until the mess in Washington is cleared (to a certain extent) but even when that happens will we likely still be in a macro world but with a tail wind instead of a head wind. That being said, the sector seemed to ne relatively heavy today even […]

October 11- Morning note

Well, we have three straight days of interesting news with ECYT rounding out the week. I want to focus on that today and get this out earlier than usual as this could be actionable today. 1. Before diving into ECYT, GS was out with a report on PCYC where they raised their price target to […]

October 1- EOD

It was a fairly busy day today in biotech land the sentiment certainly appears more positive. They participated in the market rally even though most were not big losers in the recent macro selling. This is certainly positive going forward. I want to focus on the MRK news as it touches on a lot of […]

September 27- EOD

Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a red day. 1. Well, it looks like JNJ is tossing another wrench in ECYT trials with more doxil supply problems. ECYT noted that they have […]

September 24- EOD

Not a lot going on today, which works out well as it has been a busy day for me outside of biotech. The market seemed to find its footing a little and biotechs appeared (dare I say it) a shade stronger than usual. A day does certainly not make a trend but I suspect that […]

September 24- EOD

Not a lot going on today, which works out well as it has been a busy day for me outside of biotech. The market seemed to find its footing a little and biotechs appeared (dare I say it) a shade stronger than usual. A day does certainly not make a trend but I suspect that […]

September 24- EOD

Not a lot going on today, which works out well as it has been a busy day for me outside of biotech. The market seemed to find its footing a little and biotechs appeared (dare I say it) a shade stronger than usual. A day does certainly not make a trend but I suspect that […]

September 20- Daily Update – SRPT

Obviously the big news of the day was the failure of drisapersen in their phase III trial and what it means for etperlirsen and SRPT. While it is not clear if this was RNA related but biotechs were generally weak, although not dramatically so. Before diving into the drisapersen, I want to touch on a […]

September 19- EOD

It was a relatively quiet news day. I was not sure there would be much to write about and there is nothing really new or compelling. There are some quick hitters for today and hopefully we can get some more news going tomorrow and next week. 1. I wrote a response to the ARIA bear […]

September 16- EOD

It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]

September 16- EOD

It was a strong day in the market but a weak day in biotech. That being said I think there was a definite pattern in that the large caps and biopharmas seemed to outperform (although they were still weaker than the market) than the mid- and small- caps. In my mind, I read that as […]